The status of platinum anticancer drugs in the clinic and in clinical trials
Abstract
Since its approval in 1979
- This article is part of the themed collection: Celebrating 50 years of Dalton Transactions: Our Top 50
Maintenance work is planned from 21:00 BST on Tuesday 20th August 2024 to 21:00 BST on Wednesday 21st August 2024, and on Thursday 29th August 2024 from 11:00 to 12:00 BST.
During this time the performance of our website may be affected - searches may run slowly, some pages may be temporarily unavailable, and you may be unable to log in or to access content. If this happens, please try refreshing your web browser or try waiting two to three minutes before trying again.
We apologise for any inconvenience this might cause and thank you for your patience.
* Corresponding authors
a
Strathclyde Institute of Pharmacy, and Biomedical Sciences, University of Strathclyde, John Arbuthnott Building, 27 Taylor Street, Glasgow, UK
E-mail:
nial.wheate@strath.ac.uk
Fax: +44 141 548 4962
Since its approval in 1979
N. J. Wheate, S. Walker, G. E. Craig and R. Oun, Dalton Trans., 2010, 39, 8113 DOI: 10.1039/C0DT00292E
To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.
If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.
If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content